1. Home
  2. BBIO vs FTEL Comparison

BBIO vs FTEL Comparison

Compare BBIO & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$75.68

Market Cap

14.4B

Sector

Health Care

ML Signal

HOLD

Logo Fitell Corporation

FTEL

Fitell Corporation

HOLD

Current Price

$0.65

Market Cap

9.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBIO
FTEL
Founded
2015
2007
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
9.1M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
BBIO
FTEL
Price
$75.68
$0.65
Analyst Decision
Strong Buy
Analyst Count
21
0
Target Price
$76.24
N/A
AVG Volume (30 Days)
2.0M
11.2M
Earning Date
10-29-2025
11-17-2025
Dividend Yield
N/A
30.88%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$353,780,000.00
$5,200,138.00
Revenue This Year
$128.44
N/A
Revenue Next Year
$76.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
62.46
16.42
52 Week Low
$25.34
$0.61
52 Week High
$76.51
$792.00

Technical Indicators

Market Signals
Indicator
BBIO
FTEL
Relative Strength Index (RSI) 65.57 33.04
Support Level $73.48 $0.61
Resistance Level $75.92 $0.70
Average True Range (ATR) 2.37 0.16
MACD -0.27 0.06
Stochastic Oscillator 88.96 2.90

Price Performance

Historical Comparison
BBIO
FTEL

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About FTEL Fitell Corporation

Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.

Share on Social Networks: